Paul Ludmer, MD
Cardiovascular Disease · Oakland, CANPI 1316976913
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $13,825 of the $17,430 with a category attached, or 79.3%. Boston Scientific accounts for 99.9% of it on its own, with 1 other manufacturer making up the rest. Reporting peaked in 2019 at $5,599 and has fallen 99.3% since, to $38 in 2025.
Across 72 payments — averaging $242.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$17K
- Edwards Lifesciences$20
Across 8 payments — averaging $1268.85 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boston Scientific$10K
What the payments were for
- Consulting fees$13,82579%
- Travel & lodging$1,69010%
- Food & beverage$1,91511%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 71 | $17,410 |
| Edwards Lifesciences | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GENERAL - THERAPIES$15,626
- GENERAL VASCULAR ACCESS$385
How this compares
$17,430 in reported general payments places this provider in the 85th percentile of 2,184 cardiovascular disease providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 211 | $275,637 |
| XareltoRivaroxaban | 123 | $169,079 |
| JardianceEmpagliflozin | 166 | $139,542 |
| EntrestoSacubitril/Valsartan | 91 | $114,715 |
| FarxigaDapagliflozin Propanediol | 24 | $20,425 |
| Repatha SureclickEvolocumab | 17 | $14,472 |
| Metoprolol Succinate | 232 | $4,165 |
| Atorvastatin Calcium | 257 | $3,454 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 45 | $2,628 |
| Flecainide Acetate | 34 | $2,102 |
| Ezetimibe | 62 | $1,848 |
| Propafenone Hcl ErPropafenone Hcl | 11 | $1,636 |
| Carvedilol | 131 | $1,556 |
| Rosuvastatin Calcium | 77 | $1,448 |
| Digoxin | 44 | $760 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Oakland
- Sam TeichmanOakland$183K
- Ted LoveHillsborough$102.8M
- Paul KurthSanta Barbara$6.1M
- Jason RogersSacramento$4.4M
- Matthew BudoffTorrance$3.6M
- Eric Topolla Jolla$2.2M
- Cathleen Bairey-MerzLos Angeles$1.2M
- Gagan SinghSacramento$1.2M
- Pam Taubla Jolla$1.2M
- Wilber SuStanford$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.